Levetiracetam (Keppra)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Keppra is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Keppra is indicated as adjunctive therapy: in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12...
Product first approved 2000EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (45)
Epilepsy
NCT04573803 · Cambridge University Hospitals NHS Foundation Trust
2021-03-01 – 2028-03-01 · Traumatic Brain Injury, Post Traumatic Seizures
What this study did
NCT05722951 · Tanta University
2022-10-18 – 2024-06-20 · Epilepsy
What this study did
NCT01960075 · University of Virginia
2015-10 – 2019-05 · Benzodiazepine Refractory Status Epilepticus
What this study did
NCT02726867 · Mid-Atlantic Epilepsy and Sleep Center, LLC
2014-02 – 2016-11 · Epilepsy, Status Epilepticus
What this study did
NCT01398956 · UCB Pharma
2011-06 – 2016-04 · Epilepsy, Generalized Tonic-clonic Seizures
What this study did
NCT01891890 · Emory University
2013-08 – 2015-10-23 · Epilepsy, Partial, Epilepsy, Localization Related
What this study did
NCT01392768 · Ache Laboratorios Farmaceuticos S.A.
2013-01 – 2015-08 · Epilepsy, Partial Seizures
What this study did
NCT01345058 · Brigham and Women's Hospital
2011-08-01 – 2014-10-21 · Epilepsy
What this study did
NCT01228747 · UCB Japan Co. Ltd.
2010-10 – 2014-05 · Epilepsy, Generalized Tonic-Clonic Seizures
What this study did
NCT01063764 · UCB Japan Co. Ltd.
2010-01 – 2013-10 · Epilepsy, Partial Seizures
What this study did
NCT01150331 · Assistance Publique - Hôpitaux de Paris
2009-07 – 2013-10 · Status; Epilepticus, Tonic-clonic
What this study did
NCT01292837 · UCB Japan Co. Ltd.
2011-02 – 2013-06 · Epilepsy, Generalized Tonic-clonic Seizures
What this study did
NCT01375374 · UCB Pharma
2011-07 – 2013-03 · Epilepsy, Partial
What this study did
NCT00537238 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-10 – 2012-05 · Partial Seizures
What this study did
NCT00566046 · Rennes University Hospital
2007-11 – 2010-05 · Epilepsy, Post-Traumatic
What this study did
NCT00542802 · Scienze Neurologiche Ospedaliere
2007-09 – 2009-06 · Epileptic Seizures, Stroke
What this study did
NCT00242606 · Philipps University Marburg
2005-03 – 2009-01 · Epilepsy
What this study did
NCT00471744 · Ludwig-Maximilians - University of Munich
2006-06 – 2008-07 · Epilepsy, Rolandic
What this study did
NCT00376766 · University Hospital, Grenoble
2007-02 – 2008-04 · Epilepsy, Drug Resistant
What this study did
NCT00150748 · UCB Pharma SA
2001-11 – 2007-07 · Generalized Epilepsy
What this study did
NCT00150813 · UCB Pharma SA
2005-08-10 – 2007-05-29 · Epilepsy, Tonic-clonic
What this study did
NCT00150787 · UCB Pharma
2003-07 – 2005-11 · Epilepsy, Tonic-clonic
What this study did
NCT00150735 · UCB Pharma
2002-06 – 2005-07 · Generalized Epilepsy
What this study did
NCT00152373 · UCB Pharma
2004-07 – 2005-05 · Epilepsy, Partial
What this study did
NCT00150774 · UCB Pharma
2001-11 – 2004-12 · Generalized Convulsive Epilepsy
What this study did
NCT00160628 · UCB Pharma
2004-03 – 2004-10 · Epilepsy, Partial
What this study did
Focal Onset Seizures
NCT01954121 · UCB Pharma SA
2013-09 – 2015-09 · Epilepsy, Partial Seizures
What this study did
NCT01506882 · UCB Japan Co. Ltd.
2011-12 – 2015-04 · Epilepsy, Partial Onset Seizures
What this study did
NCT00367432 · UCB Japan Co. Ltd.
2006-07 – 2010-12 · Epilepsies, Partial
What this study did
NCT00152516 · UCB Pharma
2004-10 – 2008-06 · Epilepsy, Partial
What this study did
NCT00280696 · UCB Japan Co. Ltd.
2005-11 – 2007-11 · Epilepsies, Partial
What this study did
NCT00160615 · UCB Japan Co. Ltd.
2001-09-12 – 2007-01-17 · Epilepsy, Partial
What this study did
NCT00175890 · UCB Pharma
2004-10 – 2007-01 · Epilepsy, Partial
What this study did
Primary Generalized Tonic-Clonic Seizures
Other / comorbidity
NCT07220902 · Nebraska Methodist Health System
2026-01-01 – 2034-07 · Severe Preeclampsia, Eclampsia Preeclampsia
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00758277 · Charite University, Berlin, Germany
2007-05 – 2009-12 · Alcohol Dependence, Alcoholic Relapse
What this study did
NCT00279617 · Lindner Center of HOPE
2006-01 – 2009-03 · Panic Disorder
What this study did
NCT00146471 · Charite University, Berlin, Germany
2006-01 – 2007-09 · Alcohol Withdrawal Syndrome
What this study did
NCT00291213 · Yale University
est. completion 2006-04 · Tardive Dyskinesia
What this study did
Phase 2/3 (3)
Epilepsy
NCT00465244 · Massachusetts General Hospital
2008-01 – 2010-05 · Seizures
What this study did
Other / comorbidity
NCT00299611 · Duke University
2005-11 – 2008-04 · Obsessive-Compulsive Disorder
What this study did
NCT00413296 · Duke University
2005-11 – 2008-03 · Post-Traumatic Stress Disorder
What this study did
Phase 2 (52)
Epilepsy
NCT07130786 · Ayal A. Aizer, MD
2025-12-23 – 2030-02 · Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
What this study did
NCT04004702 · Walter Reed National Military Medical Center
2020-01 – 2025-06 · Alzheimer Disease
What this study did
NCT04926844 · Sohag University
2021-06-20 – 2022-09-01 · Status Epilepticus, Generalized Convulsive Status Epilepticus, Status Epilepticus, Generalized, Status Epilepticus, Generalized Convulsive
What this study did
NCT03489044 · University of Oxford
2018-10-28 – 2022-03-21 · Alzheimer Disease, Epilepsy
What this study did
NCT02229123 · University Hospital, Tours
2018-02-27 – 2022-02-23 · Neonatal Seizures
What this study did
NCT02920060 · Banaras Hindu University
2015-01 – 2016-08 · Grand Mal Status Epilepticus
What this study did
NCT01982812 · University of Rochester
2014-01 – 2015-06 · Seizure, Epilepsy, Cerebral Malaria
What this study did
NCT00629889 · Dr Andrea Rossetti
2008-02 – 2013-05 · Brain and Central Nervous System Tumors, Seizure
What this study did
NCT00894010 · The Epilepsy Study Consortium
2009-05 – 2011-06 · Photosensitive Epilepsy
What this study did
NCT00603135 · University Hospital, Basel, Switzerland
2008-01 – 2010-03 · Status Epilepticus, Non-Convulsive
What this study did
NCT00505934 · UCB Pharma SA
2008-05 – 2010-03 · Epilepsy
What this study did
NCT00535392 · UCB Pharma
2007-09 – 2010-02 · Epilepsy
What this study did
NCT01463033 · Pavel Klein
2005-04 – 2010-02 · Epilepsy, Post-traumatic Epilepsy
What this study did
NCT00362141 · Medical Center Haaglanden
2006-10 – 2008-04 · Status Epilepticus
What this study did
NCT00600509 · UCB Pharma
2001-01 – 2003-07 · Epilepsy
What this study did
NCT00545012 · UCB Pharma
2000-05 – 2003-05 · Absence Seizures
What this study did
NCT00544050 · UCB Pharma
2002-09 – 2003-05 · Epilepsy
What this study did
Focal Onset Seizures
NCT01407523 · UCB Japan Co. Ltd.
2011-07 – 2012-02 · Epilepsy, Partial Onset Seizures
What this study did
NCT00105040 · UCB Pharma
2004-09 – 2007-03 · Epilepsy, Partial
What this study did
NCT00610454 · UCB Pharma
2004-06 – 2004-08 · Epilepsy
What this study did
Other / comorbidity
NCT05735717 · Masonic Cancer Center, University of Minnesota
2023-05-11 – 2030-11-30 · Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
What this study did
NCT03875638 · Beth Israel Deaconess Medical Center
2019-08-22 – 2026-02-16 · Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
What this study did
NCT01857934 · St. Jude Children's Research Hospital
2013-07-05 – 2025-12-31 · Neuroblastoma
What this study did
NCT04643327 · The University of Queensland
2021-02-09 – 2025-12 · Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
What this study did
NCT04317807 · NYU Langone Health
2020-08-27 – 2025-04-10 · Early Psychosis
What this study did
NCT04559529 · Vanderbilt University Medical Center
2020-09-23 – 2023-12-31 · Schizophrenia; Psychosis
What this study did
NCT02815410 · Seoul National University Hospital
2016-07 – 2022-06 · Glioblastoma Multiforme
What this study did
NCT03129360 · NYU Langone Health
2017-08-18 – 2021-11-03 · Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
What this study did
NCT03436433 · Duke University
2019-01-31 – 2020-12-04 · Glioma, Glioma of Brain, Brain Tumor
What this study did
NCT04277936 · Vanderbilt University Medical Center
2020-05-11 – 2020-08-31 · Schizophrenia; Psychosis
What this study did
NCT02002819 · University of Minnesota
2014-10-16 – 2020-07-21 · Alzheimer's Disease
What this study did
NCT00489281 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2008-06-23 – 2018-12-29 · Sickle Cell Disease
What this study did
NCT02199509 · National Institute of Neurological Disorders and Stroke (NINDS)
2014-07 – 2016-03 · Oromandibular Dystonia, Cranial Dystonia
What this study did
NCT01464359 · Masonic Cancer Center, University of Minnesota
2011-10 – 2013-10 · Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
What this study did
NCT00862563 · Boston Medical Center
2009-05 – 2013-08 · Alcoholism, Alcohol Dependence, Alcohol Abuse
What this study did
NCT01044758 · Johns Hopkins University
2009-12 – 2012-07 · Mild Cognitive Impairment (MCI)
What this study did
NCT00970814 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2009-10 – 2010-10 · Alcoholism
What this study did
NCT00577005 · Yale University
2007-07 – 2008-10 · Cocaine Dependence, Opioid Dependency
What this study did
NCT00593125 · Yale University
2007-01 – 2008-08 · Cocaine Dependence, Opioid Dependence
What this study did
NCT00324454 · Duke University
2006-05 – 2008-06 · Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
What this study did
NCT00627133 · Medical University of South Carolina
2008-02 – 2008-02 · Seizure, Alcohol Related
What this study did
NCT00141115 · New York State Psychiatric Institute
2004-03 – 2008-01 · Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia, Anxiety Disorders
What this study did
NCT00291733 · 1st Hospital of Social Security Services
2006-05 – 2007-10 · Levodopa Induced Dyskinesia
What this study did
NCT00760318 · University of South Florida
2005-11 – 2007-10 · Cervical Dystonia
What this study did
NCT00156689 · Vanderbilt University
2005-08 – 2007-05 · Chronic Idiopathic Axonal Polyneuropathy
What this study did
NCT00175955 · UCB Pharma
2005-05 – 2005-12 · Dyskinesia, Medication-induced
What this study did
NCT00076674 · National Institute of Neurological Disorders and Stroke (NINDS)
2004-01 – 2005-10 · Dyskinesias, Parkinson Disease
What this study did
NCT00247364 · Sleep Health Centers
2003-11 – 2005-10 · Restless Legs Syndrome
What this study did
NCT00160511 · UCB Pharma
2004-04 – 2005-09 · Neuralgia, Postherpetic
What this study did
NCT00160576 · UCB Pharma
2003-07 – 2004-11 · Idiopathic Parkinson Disease
What this study did
Phase 1/2 (8)
Epilepsy
NCT01720667 · Richard H. Haas
2013-03 – 2019-07-31 · Neonatal Seizures
What this study did
NCT02550028 · Children's Hospital of Fudan University
2015-09-01 – 2017-01-01 · Neonatal Seizures
What this study did
NCT01660672 · University of Rochester
2013-01 – 2013-07 · Seizure, Epilepsy, Cerebral Malaria
What this study did
NCT00884052 · Richard H. Haas
2007-04 – 2011-10 · Seizures, Disorder of Fetus or Newborn
What this study did
Other / comorbidity
NCT04833907 · Myrtelle Inc.
2021-04-01 – 2027-08-31 · Canavan Disease
What this study did
NCT03034356 · VA Office of Research and Development
2018-08-15 – 2024-06-30 · Schizophrenia
What this study did
NCT02348216 · Kite, A Gilead Company
2015-04-21 – 2023-07-27 · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
What this study did
NCT00620165 · Southern California Institute for Research and Education
2005-01 – 2008-03 · Essential Tremor
What this study did
Phase 1 (12)
Epilepsy
NCT03695094 · UCB Biopharma S.P.R.L.
2018-09-18 – 2019-05-30 · Epilepsy
What this study did
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT01521130 · Children's Hospital Medical Center, Cincinnati
2012-01 – 2017-07 · Benign Childhood Epilepsy With Centro-Temporal Spikes
What this study did
Other / comorbidity
NCT00227461 · Kessler Foundation
2005-09 – 2021-12 · Aphasia, Stroke
What this study did
NCT01725009 · UCB Japan Co. Ltd.
2012-10 – 2012-12 · Healthy Volunteers
What this study did
NCT01394224 · UCB Pharma
2011-06 – 2011-09 · Healthy Volunteers
What this study did
NCT00985348 · UCB Pharma
2009-09 – 2009-10 · Healthy
What this study did
NCT01131897 · Dr. Reddy's Laboratories Limited
2003-09 – 2003-11 · Healthy
What this study did
NCT01132352 · Dr. Reddy's Laboratories Limited
2003-09 – 2003-11 · Healthy
What this study did
Phase 4 (42)
Epilepsy
NCT07422233 · Nasim Tabrizi
2023-09-13 – 2026-01-20 · Epilepsy, Elderly
What this study did
NCT05969054 · Xiangya Hospital of Central South University
2023-07-05 – 2025-12-31 · Alzheimer Disease 3, Epilepsy
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT03054285 · Loyola University
2017-07-01 – 2021-04-01 · Seizures, Traumatic Brain Injury
What this study did
NCT04610879 · King's College London
2019-08-02 – 2020-09-23 · Rolandic Epilepsy
What this study did
NCT03940326 · Mazandaran University of Medical Sciences
2018-04-01 – 2019-12-01 · Epilepsy, Idiopathic Generalized
What this study did
NCT03107507 · Cairo University
2017-03-25 – 2017-12-30 · Neonatal Seizures
What this study did
NCT01974700 · Indiana University
2013-07 – 2016-02 · Intracranial Aneurysms, Seizures
What this study did
NCT01935908 · Vanderbilt University Medical Center
2013-05 – 2013-05 · Subarachnoid Hemorrhage, Seizures
What this study did
NCT00571155 · University Hospital Tuebingen
2007-12 – 2009-08 · Primary Brain Tumor, Epilepsy
What this study did
NCT00510783 · Emory University
2007-07 – 2008-12 · Tonic-clonic Seizure
What this study did
NCT01318408 · Drexel University College of Medicine
2006-11 – 2008-03 · Epilepsy
What this study did
NCT00160654 · UCB Pharma
2003-11-24 – 2006-12-12 · Epilepsy, Partial
What this study did
NCT00181116 · Johns Hopkins University
2005-03 – 2006-09 · Epilepsy
What this study did
NCT00245713 · UCB Pharma
2003-03 – 2004-11 · Epilepsy, Partial
What this study did
NCT00630357 · UCB Pharma
2003-03 – 2004-07 · Epilepsy
What this study did
NCT00631150 · UCB Pharma
2003-03 – 2004-07 · Epilepsy
What this study did
NCT00630968 · UCB Pharma
2000-08 – 2004-02 · Epilepsy
What this study did
NCT00630630 · UCB Pharma
2002-11 – 2003-11 · Epilepsy
What this study did
NCT00643500 · UCB Pharma
2002-01 – 2003-05 · Epilepsy, Partial
What this study did
Focal Onset Seizures
NCT01229735 · UCB Korea Co., Ltd.
2010-11 – 2015-05 · Epilepsy
What this study did
NCT00438451 · Johannes Gutenberg University Mainz
2007-01 – 2011-08 · Focal Epilepsy
What this study did
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
Other / comorbidity
NCT03048084 · Leiden University Medical Center
2018-02-01 – 2029-07-01 · Glioma
What this study did
NCT06866691 · Wake Forest University Health Sciences
2025-04-18 – 2027-04 · Traumatic Brain Injury
What this study did
NCT06081283 · University of North Carolina, Chapel Hill
2023-11-20 – 2025-01-22 · Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
What this study did
NCT01801072 · University of Michigan
2013-02 – 2023-10-06 · Intracranial Aneurysms, Seizure
What this study did
NCT02334722 · University of Florida
2015-08-05 – 2020-10-07 · Brain Neoplasms, Brain Cancer, Brain Tumors, Cancer of the Brain, Cancer of Brain, Seizure
What this study did
NCT01491113 · UCB Pharma
2011-11 – 2012-11 · Healthy Subjects, Renal Impairments
What this study did
NCT00393614 · Oslo University Hospital
2007-05 – 2010-03 · Subclinical Sleep-Activated Epileptiform Activity, CSWS
What this study did
NCT00325182 · Boston University
2006-01 – 2009-10 · Alcoholism
What this study did
NCT00618436 · University of Cincinnati
2007-08 – 2009-09 · Traumatic Brain Injury, Subarachnoid Hemorrhage
What this study did
NCT00307450 · Technische Universität Dresden
2006-03 – 2009-07 · Parkinson's Disease
What this study did
NCT00370838 · Harvey S. Singer
2007-02 – 2009-06 · Tic Disorders, Tourette Syndrome
What this study did
NCT00423527 · Odense University Hospital
2007-01 – 2009-01 · Multiple Sclerosis
What this study did
NCT00252954 · Danish Pain Research Center
2005-11 – 2008-12 · Injuries, Spinal Cord, Pain
What this study did
NCT00286260 · Odense University Hospital
2006-01 – 2008-10 · Painful Polyneuropathy
What this study did
NCT00584025 · University of South Florida
2007-12 – 2008-06 · Parkinson's Disease
What this study did
NCT00265109 · Butler Hospital
2004-12 – 2008-01 · Body Dysmorphic Disorder
What this study did
NCT00223223 · University of Texas Southwestern Medical Center
2005-02 – 2005-11 · Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
What this study did
Early phase / not applicable (31)
Epilepsy
NCT07163572 · Muhammad Aamir Latif
2025-01-16 – 2025-08-16 · Status Epilepticus
What this study did
NCT07163585 · RESnTEC, Institute of Research
2024-08-01 – 2025-07-31 · Epilepsy
What this study did
NCT04939675 · National Taiwan University Hospital
2021-07-01 – 2025-06-30 · Epilepsy
What this study did
NCT07052136 · RESnTEC, Institute of Research
2024-11-01 – 2025-04-30 · Status Epilepticus
What this study did
NCT07401433 · Hayat Abad Medical Complex, Peshawar
2024-04-08 – 2025-04-10 · Neonatal Seizures
What this study did
NCT04117425 · Assistance Publique - Hôpitaux de Paris
2022-04-20 – 2023-08-16 · Epilepsy in Pregnancy
What this study did
NCT04858841 · National Cheng Kung University
2020-08-01 – 2023-07-31 · Middle Cerebral Artery Stroke
What this study did
NCT06067412 · Shaheed Zulfiqar Ali Bhutto Medical University
2022-08-01 – 2023-01-31 · Status Epilepticus
What this study did
NCT01554683 · Beth Israel Deaconess Medical Center
2012-02 – 2017-07-01 · Alzheimer's Disease, Seizures
What this study did
NCT00916149 · Massachusetts General Hospital
2007-01 – 2012-10 · Epilepsy
What this study did
NCT00361010 · The Cleveland Clinic
2006-12 – 2007-12 · Epilepsy, Childhood Absence Epilepsy, Seizures
What this study did
NCT00221988 · University Hospitals Cleveland Medical Center
2004-03 – 2007-10 · Epilepsy
What this study did
NCT00415376 · Northwestern University
2007-02 – 2007-07 · Brain and Central Nervous System Tumors, Seizure, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00208520 · Dutch Epilepsy Clinics Foundation
2003-07 – 2007-06 · Adults With Tonic Clonic Seizures and/or Partial Seizures
What this study did
NCT00827320 · Roxane Laboratories
2007-06 – 2007-06 · Seizures
What this study did
NCT00826722 · Roxane Laboratories
2007-06 – 2007-06 · Seizures
What this study did
NCT00826865 · Roxane Laboratories
2005-08 – 2005-08 · Seizures
What this study did
NCT00826787 · Roxane Laboratories
2005-08 – 2005-08 · Seizures
What this study did
Other / comorbidity
NCT01666080 · Masonic Cancer Center, University of Minnesota
2012-08 – 2028-06 · Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
What this study did
NCT06224530 · King's College London
2024-07-19 – 2026-08-30 · Psychosis
What this study did
NCT02647437 · University of Colorado, Denver
2013-06 – 2024-09 · Schizophrenia
What this study did
NCT05860153 · Assiut University
2023-06-01 – 2024-08-01 · Febrile Convulsion
What this study did
NCT01685411 · Masonic Cancer Center, University of Minnesota
2013-01 – 2020-02-10 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT01137110 · Washington University School of Medicine
2010-05-01 – 2017-01-01 · Subarachnoid Hemorrhage
What this study did
NCT00774306 · Thomas Jefferson University
2009-04 – 2012-06 · Subarachnoid Hemorrhage
What this study did
NCT01168687 · University of California, San Francisco
2008-11 – 2010-11 · Alcohol Abuse, Drug Abuse
What this study did
NCT00566150 · Yale University
2005-10 – 2008-08 · Bipolar Depression
What this study did
NCT00518570 · Berkshire Health Systems
2003-11 – 2006-10 · Premenstrual Dysphoric Disorder
What this study did
NCT00262262 · Odense University Hospital
2004-03 – 2006-09 · Postoperative Pain
What this study did
NCT00203216 · Thomas Jefferson University
2002-09 – 2005-09 · Migraine
What this study did
NCT00254657 · University of California, San Francisco
2004-03 – 2005-04 · Fibromyalgia
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Phase 2/3 (1)
Epilepsy
NCT04172311 · Lady Hardinge Medical College
2019-11-14 – 2021-04-20 · Refractory Childhood Epilepsy
What this study did
Phase 1 (7)
Epilepsy
NCT00736931 · UCB Pharma
2008-07 – 2008-10 · Epilepsy
What this study did
Other / comorbidity
NCT07393022 · Desitin Arzneimittel GmbH
2025-12-17 – 2026-01-05 · Pharmacokinetic Analysis, Bioequivalence, Health Adult Subjects
What this study did
NCT00859430 · Teva Pharmaceuticals USA
2007-01 – 2007-01 · Healthy
What this study did
NCT00859521 · Teva Pharmaceuticals USA
2007-01 – 2007-01 · Healthy
What this study did
NCT00849862 · Teva Pharmaceuticals USA
2005-10 – 2005-11 · Healthy
What this study did
NCT00849485 · Teva Pharmaceuticals USA
2005-11 – 2005-11 · Healthy
What this study did
Phase 4 (1)
Epilepsy
NCT04759196 · Université de Sherbrooke
2021-03-01 – 2024-12 · Chronic Subdural Hematoma, Epilepsy; Seizure, Cortical Depression; Cortical Depolarization, Nonepileptic, Stereotypical and Intermittent Symptoms, NESIS
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT00926302 · Tri-Service General Hospital (TSGH)
2008-01 – 2009-04 · Healthy
What this study did
Appears in other studies (9)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Epilepsy
NCT02631759 · Hospices Civils de Lyon
2016-10 – 2021-06-07 · Acute intraCerebral Haemorrhage
What this study did
Other / comorbidity
NCT06851078 · Assistance Publique - Hôpitaux de Paris
2025-03-15 – 2027-06-15 · Septic Shock
What this study did
Phase 2/3 (1)
Epilepsy
NCT07046611 · Sohag University
2025-07-02 – 2026-07-01 · Generalized Convulsive Status Epilepticus
What this study did
Phase 2 (1)
Epilepsy
NCT05610085 · University of California, San Diego
2023-03-24 – 2027-12-31 · Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
What this study did
Phase 1/2 (1)
Epilepsy
NCT01239212 · Children's Hospital Medical Center, Cincinnati
2010-09 – 2011-07 · Seizures
What this study did
Phase 4 (3)
Epilepsy
NCT07072624 · All India Institute of Medical Sciences, Jodhpur
2025-07-23 – 2028-03-15 · Seizures, Traumatic Brain Injuries, Traumatic Brain Injury (TBI) Patients
What this study did
NCT06403150 · Dhaka Medical College
2023-05-15 – 2024-08-31 · Status Epilepticus
What this study did
NCT04176887 · Tanta University
2019-01-01 – 2020-08-01 · Comparison, the Efficacy of Levetireacetam, Phenytoin, Management of Pediatric Status Epilepticus
What this study did
Early phase / not applicable (1)
Epilepsy
NCT07098728 · Ministry of Health and Sports, Myanmar
2025-07-22 – 2026-06-30 · Seizure
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Levetiracetam (Keppra): this drugApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 12 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Levetiracetam (Keppra) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
Phase 4Traumatic Brain InjuryRecruiting
Est. primary completion 2027-04 · NCT06866691 · CT.gov ↗
What to watch
June 2027 (1)
Early phase / not applicableHematologic Disorders, Hemoglobinopathies, ImmunodeficienciesRecruiting
Est. primary completion 2027-06 · NCT01666080 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53 …Recruiting
Est. primary completion 2027-11-30 · NCT05735717 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 4GliomaRecruiting
Est. primary completion 2028-01-01 · NCT03048084 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2EpilepsyRecruiting
Est. primary completion 2029-02 · NCT07130786 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 3Severe Preeclampsia, Eclampsia PreeclampsiaNot yet recruiting
Est. primary completion 2033-12-31 · NCT07220902 · CT.gov ↗
What to watch

See the full readout calendar ↗